Lincoln Pharmaceuticals Ltd Stock Price Today (NSE: LINCOLN)
Fundamental Score
Lincoln Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lincoln Pharmaceuticals Ltd share price today is ₹629.75, down 2.52% on NSE/BSE as of 17 June 2026. Lincoln Pharmaceuticals Ltd (LINCOLN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.01K (Cr). The 52-week high for LINCOLN share price is ₹770.00 and the 52-week low is ₹440.00. At a P/E ratio of 12.68x, LINCOLN is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.82% and a debt-to-equity ratio of 0.00.
Lincoln Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Lincoln Pharmaceuticals Ltd share price chart: 21.89% return over the past month. 52-week high ₹770.00, 52-week low ₹440.00.
Lincoln Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹620.00 | ₹620.00 | ₹586.40 | ₹590.00 | 1.79L (Cr) | |
| ₹632.95 | ₹650.00 | ₹598.40 | ₹606.20 | 1.77L (Cr) | |
| ₹687.95 | ₹697.85 | ₹620.00 | ₹632.95 | 5.45L (Cr) | |
| ₹758.15 | ₹758.15 | ₹758.15 | ₹758.15 | 0.00 (Cr) | |
| ₹758.60 | ₹770.00 | ₹738.30 | ₹758.15 | 1.24L (Cr) | |
| ₹715.10 | ₹755.00 | ₹715.10 | ₹747.45 | 1.03L (Cr) | |
| ₹736.00 | ₹747.00 | ₹714.10 | ₹719.15 | 77.56K (Cr) | |
| ₹736.00 | ₹750.20 | ₹731.00 | ₹734.15 | 1.39L (Cr) | |
| ₹710.80 | ₹735.00 | ₹700.10 | ₹732.15 | 1.35L (Cr) | |
| ₹714.65 | ₹714.65 | ₹702.00 | ₹705.20 | 59.07K (Cr) |
Lincoln Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹632.95 | ₹650.00 | ₹586.40 | ₹590.00 | -6.79% | |
| ₹647.00 | ₹770.00 | ₹620.00 | ₹632.95 | -2.17% | |
| ₹575.00 | ₹733.00 | ₹545.00 | ₹645.80 | +12.31% | |
| ₹605.50 | ₹651.45 | ₹560.40 | ₹564.95 | -6.70% | |
| ₹458.75 | ₹677.00 | ₹452.90 | ₹631.05 | +37.56% | |
| ₹485.20 | ₹505.00 | ₹440.00 | ₹456.45 | -5.93% | |
| ₹510.00 | ₹515.00 | ₹464.40 | ₹483.95 | -5.11% | |
| ₹530.50 | ₹542.90 | ₹490.00 | ₹511.95 | -3.50% | |
| ₹531.00 | ₹545.00 | ₹518.00 | ₹529.80 | -0.23% | |
| ₹537.15 | ₹565.75 | ₹529.00 | ₹532.20 | -0.92% | |
| ₹533.00 | ₹624.40 | ₹523.00 | ₹538.65 | +1.06% | |
| ₹566.75 | ₹581.60 | ₹532.10 | ₹533.45 | -5.88% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lincoln Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lincoln Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LINCOLN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (17.28%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 12.68 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (71.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹214.56 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-24.12%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 4.74%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Lincoln Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lincoln Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lincoln Pharmaceuticals LtdLincoln Pharmac...Selected✓ LINCOLN • 531633 | 51.5/100 | ₹629.75₹630 | ₹1014.61₹1014.61 | 12.68Average 12.7 Average | 12.82%Average 12.82% Average | 17.28%Good 17.28% Good | 0.00Excellent 0.0 Excellent | 9.50%Good 9.50% Good | 10.03%Good 10.03% Good | 0.36% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Lincoln Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for LINCOLN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹41.11 | ₹483.95 | 11.8x |
| FY 2024 | ₹46.58 | ₹787.80 | 16.9x |
| FY 2023 | ₹36.40 | ₹609.50 | 16.7x |
| FY 2022 | ₹34.63 | ₹355.55 | 10.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lincoln Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by LINCOLN — dividend yield 0.36%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹3.61 Cr |
| FY 2024 | ₹3.00 Cr |
| FY 2023 | ₹3.00 Cr |
| FY 2022 | ₹3.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Lincoln Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for LINCOLN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
1.33%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-24.12%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.03%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
9.50%
Compounded annual net profit growth over 5 years
Lincoln Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LINCOLN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lincoln Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Lincoln Pharmaceuticals Ltd (LINCOLN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Lincoln Pharmaceuticals Ltd
About LINCOLN (Lincoln Pharmaceuticals Ltd)
Lincoln Pharmaceuticals Ltd is a dynamic and forward-thinking pharmaceutical company dedicated to enhancing global health through the development, manufacturing, and distribution o...f high-quality medicines. With a strong focus on innovation and patient well-being, Lincoln Pharmaceuticals strives to address diverse medical needs across a wide spectrum of therapeutic areas. The company's state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring the safety and efficacy of its products. Committed to research and development, Lincoln Pharmaceuticals continuously explores new formulations and drug delivery systems to improve treatment outcomes and patient compliance. The company's ethical business practices, coupled with its dedication to social responsibility, solidify its position as a trusted healthcare partner. Lincoln Pharmaceuticals' comprehensive product portfolio encompasses a diverse range of therapeutic categories, catering to various medical conditions and patient populations. From essential medicines addressing common ailments to specialized treatments for chronic diseases, the company's offerings are designed to improve the quality of life for individuals worldwide. A dedicated team of medical professionals and scientists work collaboratively to develop and refine formulations, ensuring optimal therapeutic benefits. By leveraging cutting-edge technology and adhering to rigorous quality control measures, Lincoln Pharmaceuticals consistently delivers safe, effective, and affordable medicines to meet the evolving healthcare needs of the global community. Beyond its domestic operations, Lincoln Pharmaceuticals has established a robust international presence, exporting its products to numerous countries across diverse continents. This global reach reflects the company's commitment to making quality healthcare accessible to people around the world. By forging strategic partnerships and navigating complex regulatory landscapes, Lincoln Pharmaceuticals continues to expand its market presence and contribute to the advancement of healthcare in emerging and developed economies alike. The company's unwavering dedication to quality, innovation, and patient-centricity positions it as a reliable and trusted provider of pharmaceutical solutions on a global scale.
Company Details
Key Leadership
Corporate Events
LINCOLN Share Price: Frequently Asked Questions
What is the current share price of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd (LINCOLN) trades at ₹629.75 on NSE and BSE. Market cap ₹1.01K (Cr). Educational data only.
What is the P/E ratio of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd has a P/E of 12.68x vs industry average 31.77x.
What is the Bull Run score for Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd has a Bull Run score of 51.5/100 based on 25+ financial parameters.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd has a dividend yield of 0.36%. Past dividends don't guarantee future payments.
What is the ROE of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd has ROE of 12.82%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd has debt-to-equity of 0.00.
Is Lincoln Pharmaceuticals Ltd a good investment?
Bull Run gives Lincoln Pharmaceuticals Ltd a score of 51.5/100. This is not investment advice — consult a SEBI-registered advisor.